For an Appointment call: 201. 996. 2997



This is a NIH sponsored trial that is being directed by Dr. Douglas Packer of the Mayo Clinic. The study will randomize 3000 patients with atrial fibrillation to treatment with catheter ablation therapy vs. medical therapy. Outcomes to be measured include mortality, symptom improvement, elimination of AF, and quality of life measures.

Dr. Glotzer is on the EKG review committee, which is responsible for interpreting all event recorder tracings, loop recorder tracings, and EKGs during the trial.

Azimilide Trial:

This is a randomized controlled trial of Azimilide (a new anti-arrhythmic drug) vs. placebo for the treatment of automatic implantable defibrillator (ICD) shocks caused by ventricular arrhythmias. The endpoints are a decrease in arrhythmia burden (ICD shocks) and a decrease in hospitalizations and medical resource use.

Crystal AF:

This is a trial of patients with unexplained stroke looking for silent atrial fibrillation. Patients who present with a stroke that does not have an obvious cause will be randomized to standard of care treatment vs. implantation of a loop recorder (Medtronic Reveal). They will be followed for 1 year to look for previously undiagnosed atrial fibrillation (which may have been the root cause of their stoke to begin with and could now be treated to prevent further stroke).


This is a study of patients who are already scheduled to undergo implantation of a dual chamber pacemaker and who have atrial fibrillation. The trial will randomize patients to standard of care vs. starting and stopping oral anticoagulant therapy based on the findings of the implanted pacemaker diagnostics and the burden of AF that is seen. The endpoints will be to improve management and outcome of patients who have AF and a risk of a stroke.

Statin Therapy for the Prevention of AF:

This is an NIH sponsored double blind, randomized, placebo-controlled trial to evaluate whether rosuvastatin therapy delays the time to first recurrence of symptomatic AF, and to evaluate whether this therapy effects mediators of inflammation. The endpoint is time to recurrence of symptomatic AF.


This study evaluates the role of multiple physiologic sensors that can be added to an implantable defibrillator with a software upgrade. The study will determine if a single sensor or a combination of sensors can predict heart failure episodes and allow a physician to intervene in the preclinical stage to avoid hospitalizations.


This study evaluates the role of closed loop sensors in biventricular implantable cardioverter defibrillators to prediagnose heart failure and treat it in the preclinical stage to avoid hospitalizations. Patients who have heart failure and standard indication for resynchronization therapy will be enrolled.
This site requires Flash Player version 10.1 or higher. You can install the latest version of the Adobe Flash Player by clicking here.